Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 cardiovascular outcomes study in type 2 diabetes with high cardiovascular risk
NL-OMON39200Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first major adverse cardiovascular event. Started Nov 2010; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON39200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39200.